Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer

Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer

Background: Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4 ) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro . Our study aimed to determine the frequency of mutat...

Full description

Bibliographic Details
Main Authors: Naomi Elster, Sinead Toomey, Yue Fan, Mattia Cremona, Clare Morgan, Karolina Weiner Gorzel, Una Bhreathnach, Malgorzata Milewska, Madeline Murphy, Stephen Madden, Jarushka Naidoo, Joanna Fay, Elaine Kay, Aoife Carr, Sean Kennedy, Simon Furney, Janusz Mezynski, Oscar Breathhnach, Patrick Morris, Liam Grogan, Arnold Hill, Susan Kennedy, John Crown, William Gallagher, Bryan Hennessy, Alex Eustace
Format: Article
Language:English
Published: SAGE Publishing 2018-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835918778297

Internet

https://doi.org/10.1177/1758835918778297

Similar Items